

Role of Primary Care Providers in Effective Management of Chronic Kidney Disease-2008




Lajos Zsom, MD
Nephrology Division, Department of Medicine, UMMC
Jackson, Mississippi


Aims of Talk

- CKD is a growing problem in MS and the US
- The progression to ESRD can be slowed
- Creatinine (or even eGFR) is not an absolute indicator of kidney function!
- Early referral to a Nephrologist may help your patient's QOL and longevity:
 - Hypertension, proteinuria and volume control
 - Electrolyte problems
 - Anemia and renal bone disease
 - Nutrition and chronic inflammation
 - Access placement
 - Incident (first year) mortality on dialysis: nutrition, catheters


ESRD Rates Continue to Rise





Kidney Failure Is a Rapidly Growing Problem



Early Treatment May Make a Difference




Prevalence of ESRD: 1991 versus 2001 (per million population)




Incident Counts & Adjusted Rates, By Primary Diagnosis

or


CKD as the extreme of the Metabolic Syndrome




Medicare, 1992-1993




Medicare, 1997-1998




Medicare, 2002-2003




EGHP, 1999-2000




EGHP, 2002-2003




Percent change in population size



CKD Predicts CVD




Degree of Albuminuria Predicts Severity of CAD



Chronic Kidney Disease = **GFR < 60 ml/min/1.73 m²** or persistent albuminuria

Mortality in Kidney Failure versus Cancer Deaths in 2000

(in Thousands)



The Risk of Kidney Failure is Not Uniform

Relative risks compared to patients of
European ancestry:

African Americans **3.8 X**


Native Americans **2.0 X**

Asians/Pacific Islander **1.3 X**

The relative risk of Hispanics compared to
non-Hispanics is about 1.5 X

Costs of Kidney Failure are High


(in \$billions for 2002)




How is Mississippi doing?

Prevalence of CKD per 1000 – USRDS 2007


Medicare <65




EGHP 50-64



Medicare 65+




EGHP 65+



Prevalence of CKD in JHS

men = solid bars; women = open bars




Awareness of CKD

JHS = solid bars; NHANES = open bars



Incidence of ESRD per million



Summary of the Problem

- Incidence and Prevalence of CKD and ESRD are increasing in the setting of poorly-controlled obesity-induced diabetes, HTN, and CVD.
- African Americans have a 4-fold higher incidence of End Stage Renal Disease than patients of European ancestry in the US. Hispanics have even greater risk. **Most are unaware of their disease.**
- Mississippi needs to address the growing population with obesity, diabetes, and CKD.

Outline

- Prevalence and Incidence of CVD and CKD
- **Timeline of CRI: Progressive Changes in Physiology and Metabolism**
- Specific Problems:
 - - slowing the progression
 - - hypertension/cardiovascular disease
 - - anemia
 - - metabolic acidosis
 - - secondary hyperparathyroidism
 - - potassium/sodium balance/nutrition
- Role of the Primary Care MD: when to refer

CHRONIC RENAL INSUFFICIENCY: GFR TIMELINE

NKF Stage	DESCRIPTION	GFR ml/min/ 1.73 m ²	COMPLICATION	PREVALENCE (adults> 20yrs)
↑ risk	At risk: DM, HTN AfrAm; Native Am	≥ 90	Microproteinuria; HTN; hyperfiltration	>20 million (> 12%)
1	Early renal damage	≥ 90	proteinuria, hematuria HTN; progression	>5.9 million (3.3%)
2	Mild renal insufficiency	60-89	Proteinuria/hematuria; HTN; progression	>5.3 million (3%)
3	Moderate renal insufficiency	30-59	Metabolic acidosis; anemia; hyperparathyroidism	>7.7 million (4.3%)
4	Severe renal insufficiency	15-29	Metabolic acidosis; anemia; hyperparathyroidism; fluid balance; potassium	0.4 million (0.2%)
5	ESRD	< 15	Metabolic acidosis; anemia; hyperparathyroidism; fluid balance; potassium + Uremia	0.4 million (0.1%) Many have already died

Renal insufficiency: Outdated definition:

Men: Serum creatinine > 1.5 mg/dL

Women: Serum creatinine > 1.2 mg/dL

Outdated Criteria for referral:

Serum creatinine; ~7-10 (BAD)

Serum Creatinine ~ 2-3 was OK

Louisiana experience with “healthy donors”

Determine an Estimate of GFR to estimate the degree of renal insufficiency

- Glomerular filtration rate (GFR) measures kidney function but is difficult to determine accurately in a clinical setting: inulin, iothalamate, iohexol, creatinine
- Creatinine excretion is affected by collection compliance, variable tubular secretion, ingestion of boiled or broiled (but not raw or fried) beef.
- **Recommendation**: Several formulas are available to estimate GFR from SCr levels in combination with other factors, such as age, body weight and gender.

Estimating the Glomerular Filtration Rate with the MDRD equation (recommended by the NIH):

GFR (ml/min/1.73 m²)

$$= 186 \times (S_{cr})^{-1.154} \times (\text{age})^{-0.203} \times$$

(0.742 if female) x (1.21 if AfAm)

Caveat: ONLY VALIDATED IN PATIENTS ALREADY DIAGNOSED WITH CKD (may be misleading in healthy people) SO ADDRESS RISK FACTORS (DM,HTN, PROTEINURIA, FAMILY HISTORY)

COCKCROFT-GAULT Equation vs MDRD Equation

$$\text{GFR} = \frac{(140 - \text{age})(\text{weight in kg})}{72 \times \text{Screatinine in mg/dL}} \quad (\times 0.85 \text{ for women})$$

3 patients with SCr levels of 1.5 mg/dL

Young Man

Age = 25 years

Weight = 100 kg

Cockcroft-Gault:

Estimated GFR =
106 mL/min

Young Woman

Age = 25 years

Weight = 50 kg

Estimated GFR =
45 mL/min

Older Woman

Age = 75 years

Weight = 45 kg

Estimated GFR =
23 mL/min

MDRD: 94

43

26

Serum creatinine is not an absolute indicator of renal function but must be modified by age, weight, muscle mass, gender, and state of health.

Outline

- Prevalence and Incidence of CVD and CKD
- Timeline of CRI: Progressive Changes in Physiology and Metabolism
- **Specific Problems:**
 - - slowing the progression
 - - hypertension/cardiovascular disease
 - - anemia
 - - metabolic acidosis
 - - secondary hyperparathyroidism
 - - potassium/sodium balance/nutrition
- Role of the Primary Care MD: when to refer

CHRONIC RENAL INSUFFICIENCY: GFR TIMELINE

NKF Stage	DESCRIPTION	GFR ml/min/ 1.73 m ²	COMPLICATION	PREVALENCE (adults> 20yrs)
↑ risk	At risk: DM, HTN AfrAm; Native Am	≥ 90	Microproteinuria; HTN; hyperfiltration, high BS	>20 million (> 12%)
1	Early renal damage	≥ 90	proteinuria, hematuria HTN; progression	>5.9 million (3.3%)
2	Mild renal insufficiency	60-89	Proteinuria/hematuria; HTN; progression	>5.3 million (3%)
3	Moderate renal insufficiency	30-59	Metabolic acidosis; anemia; hyperparathyroidism	>7.7 million (4.3%)
4	Severe renal insufficiency	15-29	Metabolic acidosis; anemia; hyperparathyroidism; fluid balance; potassium	0.4 million (0.2%)
5	ESRD	< 15	Metabolic acidosis; anemia; hyperparathyroidism; fluid balance; potassium + Uremia	0.4 million (0.1%)

Risk Factors for CKD

- Diabetes (type 1 and type 2)
- Hypertension
- Advancing age
- Proteinuria
- Family history of kidney disease
- Environmental nephrotoxins (NSAIDs)
- Race

Healthy People 2010; Nelson NA et al, Am J Nephrol, 1999; US Renal Data System. 2001 Atlas of ESRD in the United States.

Diabetic Nephropathy

- 20% to 30% of patients with type 1 or type 2 diabetes will develop nephropathy¹
- Intensive glycemic control significantly reduces the risk of development of nephropathy in diabetic patients²
- Hypertension accelerates progression of diabetic nephropathy
 - **In hypertensive patients with microalbuminuria or clinical albuminuria, treatment including ACE inhibitors³ and ARBs⁴ has been shown to delay the progression of kidney disease**

ACE = angiotensin-converting enzyme; ARB = angiotensin II receptor blocker

1. ADA. *Diabetes Care*. 2001;24(suppl 1):S69-S72; 2. DCCT. *N Engl J Med*. 1993;329:977-986; 3. Chan JC et al. *Kidney Int*. 2000;57:590-600; 4. Brenner BM et al. *N Engl J Med*. 2001;345:861-869.

Microalbuminuria: A Risk Factor for Morbidity and Mortality in Diabetic Patients

- Microalbuminuria = **Albumin excretion of 30 – 299 mg/24 h¹ –methodical, no threshold**
- Predicts proteinuria in diabetics²
- Increases risk for cardiovascular disease^{1,2}
- Increases risk for peripheral vascular disease^{1,2}

Hypertension

- CKD may exacerbate hypertension by multiple pathways¹⁻³
 - **Volume overload, chronic inflammation**
 - **Renin-angiotensin-aldosterone system stimulation with increased sympathetic activity**
 - **Vascular calcification with accelerated atherosclerosis**
- Hypertension increases the risks of cardiac disease⁴ and further decreases renal function, particularly in diabetic patients⁵
- **HTN control including ACE inhibitors and ARBs can slow deterioration of renal function in diabetic and non-diabetic patients**⁶⁻⁸

ACE = angiotensin-converting enzyme; ARB = angiotensin II receptor blocker

1. Anderson S et al. In: *Brenner & Rector's The Kidney*, 2000; 2. Laragh JH et al. In: *Brenner & Rector's The Kidney*, 2000; 3. Mailloux LU et al. *Am J Kidney Dis.* 1998;32(suppl 3):S120-S141; 4. Parfrey PS et al. *J Am Soc Nephrol.* 1999;10:1606-1615; 5. ADA. *Diabetes Care.* 2001;24(suppl 1):S69-72; 6. Lewis EJ et al. *N Engl J Med.* 1993;329:1456-1462; 7. Jafar TH et al. *Ann Intern Med.* 2001;135:73-87; 8. Brenner BM et al. *N Engl J Med.* 2001;345:861-869.

Dyslipidemia


- Abnormalities include^{1,2}
 - **Hypercholesterolemia**
 - **Hypertriglyceridemia, low HDL**
 - **Increases in LDL and VLDL cholesterol**
- Contributes to^{1,2}
 - **Coronary atherosclerosis**
 - **Increased incidence of myocardial infarction**
- Is associated with more rapid decline of kidney function^{2,3}

LDL = low-density lipoprotein; VLDL = very low-density lipoprotein


1. Zabetakis PM et al. *Am J Kidney Dis.* 2000;36(suppl 3):S31-S38; 2. Falk RJ et al. In: *Brenner & Rector's The Kidney*, 2000; 3. Mackenzie HS et al. In: *Brenner & Rector's The Kidney*, 2000.

How well do we follow these guidelines?


1.7 Probability of one or more serum creatinine-specific tests within a year, 2004 prevalent Medicare & EGHP pts, 2003




1.8 Probability of one or more microalbuminuria or proteinuria tests within a year, 2004 prevalent Medicare & EGHP pts, 2003



Medicare 65+: all non-CKD patients with diabetes & hypertension



Medicare 65+: all non-CKD patients with diabetes & hypertension



CHRONIC RENAL INSUFFICIENCY: GFR TIMELINE

NKF Stage	DESCRIPTION	GFR ml/min/1.73 m ²	COMPLICATION	PREVALENCE (adults> 20yrs)
↑ risk	At risk: DM, HTN AfrAm; Native Am	≥ 90	Microproteinuria; HTN; hyperglycemia	>20 million (> 12%)
1	Early renal damage	≥ 90	proteinuria, hematuria HTN; progression	>5.9 million (3.3%)
2	Mild renal insufficiency	60-89	Proteinuria/hematuria; HTN; progression	>5.3 million (3%)
3	Moderate renal insufficiency	30-59	Metabolic acidosis; anemia; hyperparathyroidism	>7.7 million (4.3%)
4	Severe renal insufficiency	15-29	Metabolic acidosis; anemia; hyperparathyroidism; fluid balance; potassium	0.4 million (0.2%)
5	ESRD	< 15	Metabolic acidosis; anemia; hyperparathyroidism; fluid balance; potassium + Uremia	0.4 million (0.1%)

CHRONIC RENAL INSUFFICIENCY: GFR TIMELINE

NKF Stage	DESCRIPTION	GFR ml/min/ 1.73 m ²	COMPLICATION	PREVALENCE (adults> 20yrs)
↑ risk	At risk: DM, HTN AfrAm; Native Am	≥ 90	Microproteinuria; HTN; hyperglycemia	>20 million (> 12%)
1	Early renal damage	≥ 90	proteinuria, hematuria HTN; progression	>5.9 million (3.3%)
2	Mild renal insufficiency	60-89	Proteinuria/hematuria; HTN; progression	>5.3 million (3%)
3	Moderate renal insufficiency	30-59	Metabolic acidosis; anemia; hyperparathyroidism	>7.7 million (4.3%)
4	Severe renal insufficiency	15-29	Metabolic acidosis; anemia; hyperparathyroidism; fluid balance; potassium	0.4 million (0.2%)
5	ESRD	< 15	Metabolic acidosis; anemia; hyperparathyroidism; fluid balance; potassium + Uremia	0.4 million (0.1%)

Care of patients with GFR > 90

- Renal ultrasound: size, shape, echogenicity; r/o hydronephrosis
- Metabolic screens: HbA1C, fasting lipids, protein quantitation serum electrolytes
- Stop NSAIDS
- **Refer to nephrologist for evaluation**

Interventions for At-Risk Patients

- Control BP: ACEI, ARB, β - and Ca Channel Blockers, etc
- Control Na intake
- Control BGs: DCCT KI 1995; 47:1703.
- Control Lipids: Statins (may decrease chronic inflammation)!
- Nutrition: lower protein intake: MDRD NEJM 1994; 330:877.
- Avoid toxic drugs: NSAIDS (includes Cox-2 I)
- Stop smoking
- **Weight reduction, exercise!**
- Check for proteinuria rise in serum creatinine
- For diabetic patients: follow the urine albumin to creatinine ratio (initial screening) or protein/creatinine if proteinuria already present (>200 mg/day)

Interventions for Mild CKD

- Treat HTN, volume, proteinuria, BS control, lipids
- Lifestyle modification (salt, protein intake, weight loss, exercise, stop smoking)
- Follow blood chemistries regularly
- Identify and stop nephrotoxins

CHRONIC RENAL INSUFFICIENCY: GFR TIMELINE

NKF Stage	DESCRIPTION	GFR ml/min/ 1.73 m ²	COMPLICATION	PREVALENCE (adults> 20yrs)
↑ risk	At risk: DM, HTN AfrAm; Native Am	≥ 90	Microproteinuria; HTN; hyperglycemia	>20 million (> 12%)
1	Early renal damage	≥ 90	proteinuria, hematuria HTN; progression	>5.9 million (3.3%)
2	Mild renal insufficiency	60-89	Proteinuria/hematuria; HTN; progression	>5.3 million (3%)
3	Moderate renal insufficiency	30-59	Metabolic acidosis; anemia; hyperparathyroidism	>7.7 million (4.3%)
4	Severe renal insufficiency	15-29	Metabolic acidosis; anemia; hyperparathyroidism; fluid balance; potassium	0.4 million (0.2%)
5	ESRD	< 15	Metabolic acidosis; anemia; hyperparathyroidism; fluid balance; potassium + Uremia	0.4 million (0.1%)

COCKCROFT-GAULT EQUATION

$$SCr = \frac{(140 - \text{age})(\text{weight in kg})}{72 \times \text{GFR (ml/min)}} \quad (\times 0.85 \text{ for women})$$

3 patients with GFR 30-59 ml/min/1.73 m²

Young Man

Age = 25 years

Weight = 100 kg

Estimated Cr =
5.3 – 2.7

Young Woman

Age = 25 years

Weight = 50 kg

Estimated Cr =
2.3 - 1.1

Older Woman

Age = 75 years

Weight = 45 kg

Estimated Cr > 1.1

MDRD: 4.2-2.2

1.8-1.1


1.4-1.1

Moderate CKD


- Anemia: variable production of erythropoietin; iron deficiency almost universal; anemia is often associated with nephrotic syndrome, slow GI bleed
- Metabolic acidosis: as the kidney fails to recover sufficient HCO_3^- , bone is used as a buffer -diet, diuretics
- Hyperphosphatemia: develops as phosphate cannot be sufficiently cleared. Hypocalcemia follows due to lack of 1-25 OH-Vitamin D_3 production by kidney and to “salting out”. Secondary hyperparathyroidism is one of the complications from this process.
- Incipient nutritional deficiencies develop with the protein malnutrition/chronic inflammation syndrome
- Variations in drug metabolism and excretion (insulin, antibiotics).

Prevalence of LVH during CRI

Levin. AJKD 1999; 34:125.



Consequences of Hypertension and Anemia: Cardiac Remodeling




LVH = left ventricular hypertrophy; LVM = LV mass; LVEDV = LV end-diastolic volume.

Lopez-Gomez JM et al. *Kidney Int.* 1998;54:S92-S98; London GM et al. *Adv Ren Replace Ther.* 1997;4:194-211; *Casale et al. *Ann Intern Med* 1986;10:173-178.


Anemia of CKD Has Many Consequences

- **Lethargy¹**
- **Confusion¹**
- **Cardiac enlargement^{2,3}**
- **Angina^{1,5}**
- **Impaired cognition⁴**
- **Impaired immune system⁴**
- **Tinnitus^{4,5}**
- **Reduced exercise capacity⁴**



- **Weakness^{1,4}, nausea**
- **Shortness of breath^{1,4,5}**
- **Palpitations^{4,5}**
- **Impaired libido/impotence⁴**
- **Headache^{4,5}**
- **Pallor^{4,5}**
- **Edema^{4,5}**
- **Paresthesia in fingers and toes⁵**

Higher Hematocrit Is Associated With a Lower Risk of Hospitalization (ESRD)



Hyperphosphatemia in CKD

- Results from PO_4^{-2} retention by failing kidney
- Forms precipitates at $\text{Ca} \times \text{P}$ product of > 70
- Results in soft tissue calcifications, vascular calcifications, and calciphylaxis
- **Increases morbidity and mortality**

Slatopolsky et al AJKD 2001; 37(suppl 2): S54.

Cardiac Calcification Predicts Ischemic CVD

- 205 hemodialysis patients studied w electron-beam tomography
- coronary artery calcification = independent predictor of CVD
- increased in older age, white males w DM, HD, high $\text{Ca} \times \text{P}$.

Raggi. J Am Col Cardiology 2002; 39:695.

Treatment of Hyperphosphatemia and Secondary Hyperparathyroidism

- **Limit Ca x P as close to normal as possible by decreasing PO₄ intake + use binders**
 -
- **iPTH: try to maintain slightly above upper limit of normal (vitamin D analogs)**

Monitoring CKD and Related Complications: Laboratory and Clinical Checklist

Laboratory Test	Normal Values	Recommended Targets
<input type="checkbox"/> BP (mm Hg)	< 120/80	< 130/80
<input type="checkbox"/> Hb (g/dL)	13.5 – 17.5	11 to 12
<input type="checkbox"/> TSAT	20 – 50%	> 20%
<input type="checkbox"/> HbA_{1c} (%)	4.55 – 5.55	< 7
<input type="checkbox"/> Phosphorus	<4	< 5.5

CHRONIC RENAL INSUFFICIENCY: GFR TIMELINE

NKF Stage	DESCRIPTION	GFR ml/min/ 1.73 m ²	COMPLICATION	PREVALENCE (adults> 20yrs)
↑ risk	At risk: DM, HTN AfrAm; Native Am	≥ 90	Microproteinuria; HTN; hyperglycemia	>20 million (> 12%)
1	Early renal damage	≥ 90	proteinuria, hematuria HTN; progression	>5.9 million (3.3%)
2	Mild renal insufficiency	60-89	Proteinuria/hematuria; HTN; progression	>5.3 million (3%)
3	Moderate renal insufficiency	30-59	Metabolic acidosis; anemia; hyperparathyroidism	>7.7 million (4.3%)
4	Severe renal insufficiency	15-29	anemia; hyperparathyroidism; fluid balance; malnutrition	0.4 million (0.2%)
5	ESRD	< 15	Metabolic acidosis; anemia; hyperparathyroidism; fluid balance; potassium + Uremia	0.4 million (0.1%)

COCKCROFT-GAULT EQUATION

$$SCr = \frac{(140 - \text{age})(\text{weight in kg})}{72 \times \text{GFR (ml/min)}} \quad (\times 0.85 \text{ for women})$$

3 patients with GFR 15-29 ml/min/1.73 m²

Young Man

Age = 25 years

Weight = 100 kg

Estimated Cr =
10.6-5.3

Young Woman

Age = 25 years

Weight = 50 kg

Estimated Cr =
4.6-2.3

Older Woman

Age = 75 years

Weight = 45 kg

Estimated Cr =
2.1-1.1

MDRD: 7.4-4.2

3.5-1.8

2.4-1.4

Patient #1: 85 yo, sedentary female, 42 kg, lives with her extended family. Her family has noted over the last 6 months, that **her appetite has decreased** and that she seems to nap a lot during the day. Her BP is normal and she is not diabetic, but she has not seen a doctor since her children were born. Blood chemistries reveal:

BUN = 10; Cr = 2.5; PO₄ = 3.0; HCO₃ = 20; HCT = 30; Ca = 8.2; **Alb = 3.0**


Patient #2: 38 yo male, 110 kg, works construction and says he “hasn’t felt right for weeks”. BP = 190/115; Blood chemistries: Cr = 10.0; BUN = 110; PO₄ = 8.0; HCO₃ = 18; HCT = 30; Ca = 8.0; **Alb = 4.1**.

Who is more uremic and closer to ESRD?

Nutritional Challenges in CKD

- As the kidney fails, protein intake should be maintained at 1 g/kg/day (early on this is a reduction later on it may be an increase) and caloric intake at 25-35 kcal/kg/day. These goals, if not approached carefully with a disciplined diet, often result in:
 - hyperphosphatemia
 - hyperkalemia
 - uremia
 - hypoalbuminemia ± elevated CRP
 - metabolic acidosis
 - iron deficiency

Hypoalbuminemia at Dialysis Initiation: Mortality Association




CHRONIC RENAL INSUFFICIENCY: GFR TIMELINE

NKF Stage	DESCRIPTION	GFR ml/min/1.73 m ²	COMPLICATION	PREVALENCE (adults> 20yrs)
↑ risk	At risk: DM, HTN AfrAm; Native Am	≥ 90	Microproteinuria; HTN; hyperglycemia	>20 million (> 12%)
1	Early renal damage	≥ 90	proteinuria, hematuria HTN; progression	>5.9 million (3.3%)
2	Mild renal insufficiency	60-89	Proteinuria/hematuria; HTN; progression	>5.3 million (3%)
3	Moderate renal insufficiency	30-59	Metabolic acidosis; anemia; hyperparathyroidism	>7.7 million (4.3%)
4	Severe renal insufficiency	15-29	Metabolic acidosis; anemia; hyperparathyroidism; fluid balance; potassium	0.4 million (0.2%)
5	ESRD	< 15	Metabolic acidosis; anemia; hyperparathyroidism; fluid balance; potassium + Uremia	0.4 million (0.1%)

If referred at this stage.....


- Hypervolemia, CHF, uncontrolled BP
- Malnutrition, chronic inflammation: increased cardiac and infectious morbidity
- Untreated anemia, renal bone disease
- Delays in modality teaching and transplant workup and referral (pre-emptive transplant....)
- Access problems (temporary access: increased mortality)
- Etiology for enormous incident mortality (first year) on hemodialysis

Primary Care Survey: Comfort With CKD Treatment



Ratings of comfort with each area of CKD treatment on a scale of 0 (low) to 5 (high) by 105 primary care physicians from Long Island, NY.

Proposed Collaborative Relationships in Treating CKD



Summary

Consequences of CKD if left untreated:

↑ **Progression to ESRD**

↓ **QOL**

↑ **LVH**

↑ **Malnutrition**

↑ **Hospitalization**

↑ **Mortality**

Conclusions

- CKD is a growing problem in MS and the US
- The progression to ESRD can be slowed sometime stopped by controlling blood pressure and diabetes, proteinuria and with lifestyle modifications.
- Creatinine is not an absolute indicator of kidney function- we use **global multidisciplinary clinical assessment** plus estimated GFR.
- Early referral to a Nephrologist may help your patient's QOL and longevity